
LINK . SPRINGER . COM {
}
Title:
The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019 | Drugs
Description:
The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Science
- Education
- Health & Fitness
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We don’t know how the website earns money.
Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.
Keywords {🔍}
moxifloxacin, treatment, tuberculosis, article, google, scholar, patients, levofloxacin, drug, clinical, regimen, regimens, rifampicin, gatifloxacin, van, cas, drugs, pulmonary, study, tbm, trials, standard, trial, fluoroquinolones, resistance, compared, meningitis, dose, agents, dis, highdose, survival, outcome, sterilizing, dstb, health, analysis, data, based, drugresistant, month, phase, groningen, antitb, results, table, respir, infect, fluoroquinolone, months,
Topics {✒️}
rr/mdr-tb patient data core rr/mdr-tb agents thrice-weekly ds-tb regimen high-dose anti-tb drugs suppress drug-resistant mutants internal medicine/infectious diseases intensified antituberculosis therapy totally drug-resistant strains pre-clinical animal models disease-related intestinal dysfunction article download pdf totally drug-resistant tuberculosis world health organization powerful anti-tb agents extended pk/pd analysis core anti-tb drugs line anti-tb agents combination therapy pre-clinical study designs line anti-tb drugs mdr/rr-tb regimen mdr/rr-tb regimen [47] additional pk/pd analysis drug-resistant tb prevention hollow-fiber infection model sixth month post-treatment shorten ds-tb treatment tuberculous meningitis—authors’ reply vitro pk/pd modelling rr/mdr-tb regimens rr/mdr-tb patients [8] mdr/rr-tb patients pulmonary multidrug-resistant tuberculosis adequate early-phase treatment standard ds-tb regimen multidrug-resistant tuberculosis treatment individual patient data privacy choices/manage cookies standard ds-tb treatment thrice-weekly 4-month moxifloxacin �randomized controlled trial” mdr-tb treatment success included high-dose fluoroquinolone conventional mdr-tb regimens group analysis showed standard drug combination van der werf pubmed search mdr/rr-tb lean body mass
Schema {🗺️}
WebPage:
mainEntity:
headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
datePublished:2019-01-07T00:00:00Z
dateModified:2019-01-07T00:00:00Z
pageStart:161
pageEnd:171
sameAs:https://doi.org/10.1007/s40265-018-1043-y
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
isPartOf:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019
description:The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs. However, based on their pharmacokinetics (PK) and pharmacodynamics (PD), these drugs are also promising for TB meningitis and might perhaps have the potential to shorten pulmonary TB treatment if dosing could be optimized. We prepared a comprehensive summary of clinical trials investigating the outcome of TB regimens based on moxifloxacin, gatifloxacin and levofloxacin in recent years. In the majority of clinical trials, treatment success was not in favour of these drugs compared to standard regimens. By discussing these results, we propose that incorporation of extended PK/PD analysis into the armamentarium of drug-development tools is needed to clarify the role of moxifloxacin, gatifloxacin and levofloxacin for TB, using the right dose. In addition, to prevent failure of treatment or emergence of drug-resistance, PK and PD variability advocates for concentration-guided dosing in patients at risk for too low a drug-exposure.
datePublished:2019-01-07T00:00:00Z
dateModified:2019-01-07T00:00:00Z
pageStart:161
pageEnd:171
sameAs:https://doi.org/10.1007/s40265-018-1043-y
keywords:
Pharmacotherapy
Pharmacology/Toxicology
Internal Medicine
image:
isPartOf:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
type:
Periodical
PublicationVolume
publisher:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Drugs
issn:
1179-1950
0012-6667
volumeNumber:79
Organization:
name:Springer International Publishing
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:A. D. Pranger
url:http://orcid.org/0000-0001-5920-0734
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:Leiden University Medical Center
address:
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
type:PostalAddress
type:Organization
email:[email protected]
name:T. S. van der Werf
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:J. G. W. Kosterink
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:University of Groningen
address:
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
name:J. W. C. Alffenaar
affiliation:
name:University of Groningen, University Medical Center Groningen
address:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
type:PostalAddress
type:Organization
PostalAddress:
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands
name:Department of Pulmonary Diseases and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Internal Medicine/Infectious Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
name:PharmacoTherapy, Epidemiology and Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands
name:Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
External Links {🔗}(141)
- Income figures for https://www.springernature.com/gp/authors
- Revenue of https://link.springernature.com/home/
- https://order.springer.com/public/cart's revenue stream
- Monthly income for https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
- Financial intake of https://www.editorialmanager.com/drua
- Check the income stats for https://orcid.org/0000-0001-5920-0734
- What's the financial gain of https://beta.springernature.com/pre-submission?journalId=40265?
- How much does https://doi.org/10.1016%2FS0140-6736%2814%2960844-8 generate monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Global%2C%20regional%2C%20and%20national%20incidence%20and%20mortality%20for%20HIV%2C%20tuberculosis%2C%20and%20malaria%20during%201990%E2%80%932013%3A%20a%20systemic%20analysis%20for%20the%20Global%20Burden%20of%20Disease%20study%202013&journal=Lancet&doi=10.1016%2FS0140-6736%2814%2960844-8&volume=384&issue=9947&pages=1005-1070&publication_year=2014&author=Murray%2CCJ&author=Ortblad%2CKF&author=Guinovart%2CC rake in every month?
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25792630's revenue stream
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391660 make?
- How much does http://scholar.google.com/scholar_lookup?&title=Towards%20tuberculosis%20elimination%3A%20an%20action%20framework%20for%20low-incidence%20countries&journal=Eur%20Respir%20J.&volume=45&issue=4&pages=928-952&publication_year=2015&author=L%C3%B6nnroth%2CK&author=Migliori%2CGB&author=Abubakar%2CI earn?
- How much income does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17868596 have?
- How much does http://scholar.google.com/scholar_lookup?&title=First%20tuberculosis%20cases%20in%20Italy%20resistant%20to%20all%20tested%20drugs&journal=Eurosurveillance.&volume=12&issue=5&publication_year=2007&author=Migliori%2CGB&author=Laco%2CG&author=Besozzi%2CG&author=Centis%2CR&author=Cirillo%2CDM net monthly?
- Earnings of https://doi.org/10.1378%2Fchest.08-2427
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Emergence%20of%20new%20forms%20of%20totally%20drug-resistant%20tuberculosis%20bacilli%3A%20super%20extensively%20drug-resistant%20tuberculosis%20or%20totally%20drug-resistant%20strains%20in%20iran&journal=Chest&doi=10.1378%2Fchest.08-2427&volume=136&issue=2&pages=420-425&publication_year=2009&author=Velyati%2CAA&author=Masjedi%2CMR&author=Farnia%2CP&author=Tabarsi%2CP&author=Ghanavi%2CJ&author=Ziazarifi%2CAH&author=Hoffner%2CSE
- What's the income generated by https://doi.org/10.1093%2Fcid%2Fcir889 each month?
- How much does http://scholar.google.com/scholar_lookup?&title=Totally%20drug-resistant%20tuberculosis%20in%20India&journal=Clin%20Infect%20Dis&doi=10.1093%2Fcid%2Fcir889&volume=54&issue=4&pages=579-581&publication_year=2012&author=Udwadia%2CZF&author=Amale%2CRA&author=Ajbani%2CKK&author=Rodrigues%2CC generate monthly?
- Get to know https://doi.org/10.1183%2F13993003.02308-2016's earnings
- Monthly income for http://scholar.google.com/scholar_lookup?&title=World%20Health%20Organization%20treatment%20guidelines%20for%20drug-resistant%20tuberculosis%2C%202016%20update&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.02308-2016&volume=49&issue=3&publication_year=2017&author=Falzon%2CD&author=Sch%C5%B1nemann%2CHJ&author=Harausz%2CE&author=Gonz%C3%A1lez-Angulo%2CL&author=Lienhardt%2CC&author=Jaramillo%2CE&author=Weyer%2CK
- How much does https://doi.org/10.2174%2F138161211797470200 pull in?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Fluoroquinolones%2C%20the%20cornerstone%20of%20treatment%20of%20drug-resistant%20tuberculosis%3A%20a%20pharmacokinetic%20and%20pharmacodynamics%20approach&journal=Curr%20Pharm%20Des&doi=10.2174%2F138161211797470200&volume=17&issue=27&pages=2900-2930&publication_year=2011&author=Pranger%2CAD&author=Alffenaar%2CJW&author=Aarnoutse%2CRE have monthly?
- How much profit does http://www.fda.gov make?
- How much does http://www.ema.europe.eu rake in every month?
- How much does http://www.newtbdrugs.org rake in every month?
- Income figures for https://doi.org/10.1056%2FNEJMoa1407426
- How much does http://scholar.google.com/scholar_lookup?&title=Four-month%20moxifloxacin-based%20regimens%20for%20drug-sensitive%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1407426&volume=371&issue=17&pages=1577-1587&publication_year=2014&author=Gillespie%2CSH&author=Crook%2CAM&author=McHugh%2CTD&author=Mendel%2CCM&author=Meredith%2CSK&author=Murray%2CSR&author=Pappas%2CF&author=Phillips%2CPP&author=Nunn%2CAJ pull in monthly?
- How much does https://doi.org/10.1056%2FNEJMoa1314210 make?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=High-dose%20rifapentine%20with%20moxifloxacin%20for%20pulmonary%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1314210&volume=371&issue=17&pages=1599-1608&publication_year=2014&author=Jindani%2CA&author=Harrison%2CTS&author=Nunn%2CAJ&author=Phillips%2CPP&author=Churchyard%2CGJ&author=Charalambous%2CS&author=Hatherill%2CM&author=Geldenhuys%2CH&author=Mcllleron%2CHM&author=Zvada%2CSP&author=Mungofa%2CS&author=Shah%2CNA&author=Zizhou%2CS&author=Magweta%2CL&author=Shepard%2CJ&author=Nyirenda%2CS&author=Dijk%2CJH&author=Clouting%2CHE&author=Coleman%2CD&author=Bateson%2CAL&author=McHugh%2CTD&author=Butcher%2CPD&author=Mitchison%2CDA
- How much income does https://doi.org/10.1513%2FAnnalsATS.201510-690BC have?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Choice%20between%20levofloxacin%20and%20moxifloxacin%20and%20multidrug-resistant%20tuberculosis%20treatment%20outcomes&journal=Ann%20Am%20Thorac%20Soc.&doi=10.1513%2FAnnalsATS.201510-690BC&volume=13&issue=3&pages=364-370&publication_year=2016&author=Kang%2CYA&author=Shim%2CTS&author=Koh%2CWJ&author=Lee%2CSH&author=Lee%2CCH&author=Choi%2CJC&author=Lee%2CJH&author=Jang%2CSH&author=Yoo%2CKH&author=Jung%2CKH&author=Kim%2CKU&author=Choi%2CSB&author=Ryu%2CYJ&author=Kim%2CKC&author=Um%2CS&author=Kwon%2CYS&author=Kim%2CYH&author=Choi%2CWI&author=Jeon%2CK&author=Hwang%2CYI&author=Kim%2CSJ&author=Lee%2CHK&author=Heo%2CE&author=Yim%2CJJ?
- What's the monthly money flow for https://doi.org/10.1056%2FNEJMoa1315817?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=A%20four-month%20gatifloxacin-containing%20regimen%20for%20treating%20tuberculosis&journal=N%20Engl%20J%20Med.&doi=10.1056%2FNEJMoa1315817&volume=371&issue=17&pages=1588-1598&publication_year=2014&author=Merle%2CCS&author=Fielding%2CK&author=Sow%2COB&author=Gninafon%2CM&author=Lo%2CMB&author=Mthiyane%2CT&author=Odhiambo%2CJ&author=Amukoye%2CE&author=Bah%2CB&author=Kassa%2CF&author=N%E2%80%99Diaye%2CA&author=Rustomjee%2CR&author=Jong%2CBC&author=Horton%2CJ&author=Perronne%2CC&author=Sismanidis%2CC&author=Lapujade%2CO&author=Olliaro%2CPL&author=Lienhardt%2CC?
- Get to know what's the income of https://doi.org/10.1371%2Fjournal.pone.0067030
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=Randomized%20clinical%20trial%20of%20thrice-weekly%204-month%20moxifloxacin%20or%20gatifloxacin%20containing%20regimens%20in%20the%20treatment%20of%20new%20sputum%20positive%20pulmonary%20tuberculosis%20patients&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0067030&volume=8&issue=7&publication_year=2013&author=Jawahar%2CMS&author=Banurekha%2CVV&author=Paramasivan%2CCN&author=Rahman%2CF&author=Ramachandran%2CR&author=Venkatesan%2CP&author=Balasubramanian%2CR&author=Selvakumar%2CN&author=Ponnuraja%2CC&author=Iliayas%2CAS&author=Gangadevi%2CNP&author=Raman%2CB&author=Baskaran%2CD&author=Kumar%2CSR&author=Kumar%2CMM&author=Mohan%2CV&author=Ganapathy%2CS&author=Kumar%2CV&author=Shanmugam%2CG&author=Charles%2CN&author=Sakthivel%2CMR&author=Jaqannath%2CK&author=Chandrasekar%2CC&author=Parthasarathy%2CRT&author=Narayanan%2CPR
- Learn about the earnings of https://doi.org/10.1093%2Fjac%2Fdku103
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Safety%20and%20efficacy%20of%20levofloxacin%20versus%20rifampicin%20in%20tuberculosis%20meningitis%3A%20an%20open-label%20randomized%20controlled%20trial&journal=J%20Antimicrob%20Chemother&doi=10.1093%2Fjac%2Fdku103&volume=69&issue=8&pages=2246-2251&publication_year=2014&author=Kalita%2CJ&author=Misra%2CUK&author=Prasad%2CS&author=Bhoi%2CSK
- What is the earnings of https://doi.org/10.1056%2FNEJMoa1507062?
- How much money does http://scholar.google.com/scholar_lookup?&title=Intensified%20antituberculosis%20therapy%20in%20adults%20with%20tuberculous%20meningitis&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1507062&volume=374&issue=2&pages=124-134&publication_year=2016&author=Heemskerk%2CAD&author=Bang%2CND&author=Mai%2CNT&author=Chau%2CTT&author=Phu%2CNH&author=Loc%2CPP&author=Chau%2CNV&author=Hien%2CTT&author=Dung%2CNH&author=Lan%2CNT&author=Lan%2CNH&author=Lan%2CNN&author=Phong%2CT&author=Vien%2CNN&author=Hien%2CNQ&author=Yen%2CNT&author=Ha%2CDT&author=Day%2CJN&author=Caws%2CM&author=Merson%2CL&author=Thinh%2CTT&author=Wolbers%2CM&author=Thwaites%2CGE&author=Farrar%2CJJ make?
- How much income does https://doi.org/10.1016%2FS1473-3099%2812%2970264-5 have?
- What's the income generated by http://scholar.google.com/scholar_lookup?&title=Intensified%20regimen%20containing%20rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis%3A%20an%20open-label%20randomised%20controlled%20phase%202%20trial&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2812%2970264-5&volume=13&issue=1&pages=27-35&publication_year=2013&author=Ruslami%2CR&author=Ganiem%2CAR&author=Dian%2CS&author=Apriani%2CL&author=Achmad%2CTH&author=Ven%2CAJ&author=Borm%2CG&author=Aarnoutse%2CRE&author=Crevel%2CR each month?
- Check the income stats for https://doi.org/10.2217%2Ffmb.12.14
- Financial intake of http://scholar.google.com/scholar_lookup?&title=How%20Mycobacterium%20tuberculosis%20goes%20to%20sleep%3A%20the%20dormancy%20survival%20regulator%20DosR%20a%20decade%20later&journal=Future%20Microbiol.&doi=10.2217%2Ffmb.12.14&volume=7&issue=4&pages=513-518&publication_year=2012&author=Boon%2CC&author=Dick%2CT
- Financial intake of https://doi.org/10.1093%2Fjac%2Fdku457
- How much does http://scholar.google.com/scholar_lookup?&title=Comprehensive%20physiochemical%2C%20pharmacokinetic%20and%20activity%20profiling%20of%20anti-TB%20agents&journal=J%20Antimicrob%20Chemother&doi=10.1093%2Fjac%2Fdku457&volume=70&issue=3&pages=857-867&publication_year=2015&author=Lakshminarayana%2CSB&author=Huat%2CTB&author=Ho%2CPC&author=Manjunatha%2CUH&author=Dartois%2CV&author=Dick%2CT&author=Rao%2CSP make?
- How much revenue does https://doi.org/10.1164%2Frccm.200407-885OC produce monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Moxifloxacin-containing%20regimen%20of%20reduced%20duration%20produce%20a%20stable%20cure%20in%20murine%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.200407-885OC&volume=170&issue=10&pages=1131-1134&publication_year=2004&author=Nuermberger%2CEL&author=Yoshimatsu%2CT&author=Tyagi%2CS&author=Williams%2CK&author=Rosenthal%2CI&author=O%E2%80%99Brien%2CRJ&author=Vernon%2CAA&author=Chaisson%2CRE&author=Bishai%2CWR&author=Grosset%2CJH rake in every month?
- What's https://doi.org/10.1164%2Frccm.200901-0078OC's gross income?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Substitution%20of%20moxifloxacin%20for%20isoniazid%20during%20intensive%20phase%20treatment%20of%20pulmonary%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med.&doi=10.1164%2Frccm.200901-0078OC&volume=180&issue=3&pages=273-280&publication_year=2009&author=Dorman%2CSE&author=Johnson%2CJL&author=Goldberg%2CS&author=Muzanye%2CG&author=Padayatchi%2CN&author=Bozeman%2CL&author=Heilig%2CCM&author=Bernardo%2CJ&author=Choudhri%2CS&author=Grosset%2CJH&author=Guy%2CE&author=Guyadeen%2CP&author=Leus%2CMC&author=Maltas%2CG&author=Menzies%2CD&author=Nuermberger%2CEL&author=Villarino%2CM&author=Vernon%2CA&author=Chaisson%2CRE?
- Monthly income for https://doi.org/10.1164%2Frccm.200603-360OC
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Moxifloxacin%20versus%20ethambutol%20in%20the%20first%202%C2%A0months%20of%20treatment%20for%20pulmonary%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.200603-360OC&volume=174&issue=3&pages=331-338&publication_year=2006&author=Burman%2CWJ&author=Goldberg%2CS&author=Johnson%2CJL&author=Muzanye%2CG&author=Engle%2CM&author=Mosher%2CAW&author=Choudhri%2CS&author=Daley%2CCL&author=Munsiff%2CSS&author=Zhao%2CZ&author=Vernon%2CA&author=Chaisson%2CRE
- Learn how profitable https://doi.org/10.1016%2FS0140-6736%2809%2960333-0 is on a monthly basis
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Moxifloxacin%20versus%20ethambutol%20in%20the%20initial%20treatment%20of%20tuberculosis%3A%20a%20double-blind%2C%20randomised%2C%20controlled%20phase%20II%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2809%2960333-0&volume=373&issue=9670&pages=1183-1189&publication_year=2009&author=Conde%2CMB&author=Efron%2CA&author=Loredo%2CC&author=Souza%2CGR&author=Graca%2CNP&author=Cezar%2CMC&author=Ram%2CM&author=Chaudhary%2CMA&author=Bishai%2CWR&author=Kritski%2CAL&author=Chaisson%2CRE?
- How much profit does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18230244 generate?
- What's the income of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20the%20sterilising%20activities%20of%20ofloxacin%2C%20gatifloxacin%20and%20moxifloxacin%20in%20pulmonary%20tuberculosis&journal=Int%20J%20Tuberc%20Lung%20Dis.&volume=12&issue=2&pages=128-138&publication_year=2008&author=Rustomjee%2CR&author=Lienhardt%2CC&author=Kanyok%2CT&author=Davies%2CGR&author=Levin%2CJ&author=Mthiyane%2CT&author=Reddy%2CC&author=Sturm%2CAW&author=Sirgel%2CFA&author=Allen%2CJ&author=Coleman%2CDJ&author=Fourie%2CB&author=Mitchison%2CDA?
- What's the financial outcome of https://doi.org/10.1093%2Finfdis%2Fjiv183?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Nonclinical%20models%20for%20antituberculosis%20drug%20development%3A%20a%20landscape%20analysis&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjiv183&volume=211&issue=Suppl%203&pages=S83-S95&publication_year=2015&author=Gumbo%2CT&author=Lenaerts%2CAJ&author=Hanna%2CD&author=Romero%2CK&author=Nuermberger%2CE?
- How much does https://doi.org/10.1128%2FAAC.00105-15 net monthly?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20moxifloxacin-containing%20regimens%20in%20pathologically%20distinct%20murine%20tuberculosis%20models&journal=Antimicrob%20Agents%20Chemother&doi=10.1128%2FAAC.00105-15&volume=59&issue=7&pages=4026-4030&publication_year=2015&author=Li%2CSY&author=Irwin%2CSM&author=Converse%2CPJ&author=Mdluli%2CKE&author=Lenaerts%2CAJ&author=Nuermberger%2CEL?
- Learn how profitable https://doi.org/10.1086%2F424849 is on a monthly basis
- Earnings of http://scholar.google.com/scholar_lookup?&title=Selection%20of%20a%20moxifloxacin%20dose%20that%20suppresses%20drug%20resistance%20in%20Mycobacterium%20tuberculosis%2C%20by%20use%20of%20an%20in%20vitro%20pharmacodynamic%20infection%20model%20and%20mathematical%20modelling&journal=J%20Infect%20Dis&doi=10.1086%2F424849&volume=190&issue=9&pages=1642-1651&publication_year=2004&author=Gumbo%2CT&author=Louie%2CA&author=Deziel%2CMR&author=Parsons%2CLM&author=Salfinger%2CM&author=Drusano%2CGL
- How profitable is https://doi.org/10.1128%2FmBio.00139-10?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=The%20combination%20of%20rifampin%20plus%20moxifloxacin%20is%20synergistic%20for%20suppression%20of%20resistance%20but%20antagonistic%20for%20cell%20kill%20of%20Mycobacterium%20tuberculosis%20as%20determined%20in%20a%20hollow-fiber%20infection%20model&journal=MBio.&doi=10.1128%2FmBio.00139-10&volume=1&issue=3&publication_year=2010&author=Drusano%2CGL&author=Sqambati%2CN&author=Eichas%2CA&author=Brown%2CDL&author=Kulawy%2CR&author=Louie%2CA generate?
- How much does https://doi.org/10.1093%2Finfdis%2Fjiu610 net monthly?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic-pharmacodynamic%20and%20dose-response%20relationships%20of%20antituberculosis%20drugs%3A%20recommendations%20and%20standards%20for%20industry%20and%20academia&journal=J%20Infect%20Dis&doi=10.1093%2Finfdis%2Fjiu610&volume=211&issue=Suppl%203&pages=S96-S106&publication_year=2015&author=Gumbo%2CT&author=Angulo-Barturen%2CI&author=Ferrer-Bazaga%2CS?
- What's the income of https://doi.org/10.1128/AAC.00751-17?
- How much does https://doi.org/10.1128%2FAAC.00751-17 earn?
- What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28839079?
- How much profit does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655093 generate?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Linezolid%20dose%20that%20maximizes%20sterilizing%20effect%20while%20minimizing%20toxicity%20and%20resistance%20emergence%20for%20tuberculosis&journal=Antimicrob%20Agents%20Chemother.&doi=10.1128%2FAAC.00751-17&publication_year=2017&author=Srivastava%2CS&author=Magombedze%2CG&author=Koeuth%2CT&author=Sherman%2CC&author=Pasipanodya%2CJG&author=Raj%2CP&author=Wakeland%2CE&author=Deshpande%2CD&author=Gumbo%2CT
- What is the monthly revenue of https://doi.org/10.1128/AAC.02039-16?
- Learn how profitable https://doi.org/10.1128%2FAAC.02039-16 is on a monthly basis
- What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28696238?
- Earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571313
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=The%20sterilizing%20effect%20of%20ertapenem-clavulanate%20in%20a%20hollow%20fiber%20model%20of%20tuberculosis%20and%20implications%20on%20clinical%20dosing&journal=Antimicrob%20Agents%20Chemother.&doi=10.1128%2FAAC.02039-16&publication_year=2017&author=Rijn%2CSP&author=Srivastava%2CS&author=Wessels%2CMA&author=Soolingen%2CD&author=Alffenaar%2CJC&author=Gumbo%2CT?
- Get to know https://doi.org/10.1183%2F09031936.00176610's earnings
- What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Evaluation%20of%20moxifloxacin%20for%20the%20treatment%20of%20tuberculosis%3A%203%C2%A0years%20of%20experience&journal=Eur%20Respir%20J&doi=10.1183%2F09031936.00176610&volume=38&issue=4&pages=888-894&publication_year=2011&author=Pranger%2CAD&author=Altena%2CR&author=Aarnoutse%2CRE&author=Soolingen%2CD&author=Uges%2CDR&author=Kosterink%2CJG&author=Werf%2CTS&author=Alffenaar%2CJW?
- What's the profit of https://doi.org/10.1016%2FS0732-8893%2899%2900007-3?
- How much profit does http://scholar.google.com/scholar_lookup?&title=Malnutrition%20in%20tuberculosis&journal=Diagn%20Microbiol%20Infect%20Dis&doi=10.1016%2FS0732-8893%2899%2900007-3&volume=34&issue=2&pages=153-157&publication_year=1999&author=Macallan%2CDC generate?
- What's the income of https://doi.org/10.1080%2F17512433.2017.1246179?
- http://scholar.google.com/scholar_lookup?&title=The%20challenges%20of%20pharmacokinetic%20variability%20of%20first-line%20anti-TB%20drugs&journal=Expert%20Rev%20Clin%20Pharmacol.&doi=10.1080%2F17512433.2017.1246179&volume=10&issue=1&pages=47-58&publication_year=2017&author=Devaleenal%2CDaniel%20B&author=Ramachandran%2CG&author=Swaminathan%2CS's total income per month
- How much revenue does https://doi.org/10.1086%2F521894 bring in?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Rifampicin%20reduces%20plasma%20concentrations%20of%20moxifloxacin%20in%20patients%20with%20tuberculosis&journal=Clin%20Infect%20Dis&doi=10.1086%2F521894&volume=45&issue=8&pages=1001-1007&publication_year=2007&author=Nijland%2CHM&author=Ruslami%2CR&author=Suroto%2CAJ&author=Burger%2CDM&author=Alisjahbana%2CB&author=Crevel%2CR&author=Aarnoutse%2CRE produce monthly?
- What's the profit of https://doi.org/10.1128%2FAAC.01621-06?
- How much does http://scholar.google.com/scholar_lookup?&title=Effect%20of%20rifampin%20and%20multidrug%20resistance%20gene%20polymorphism%20on%20concentrations%20of%20moxifloxacin&journal=Antimicrob%20Agents%20Chemother&doi=10.1128%2FAAC.01621-06&volume=51&issue=8&pages=2861-2866&publication_year=2007&author=Weiner%2CM&author=Burman%2CW&author=Luo%2CCC&author=Peloquin%2CCA&author=Engle%2CM&author=Goldberg%2CS&author=Agarwal%2CV&author=Vernon%2CA make?
- How much revenue does https://doi.org/10.1038%2Fnm.3937 bring in?
- Revenue of http://scholar.google.com/scholar_lookup?&title=The%20association%20between%20sterilizing%20activity%20and%20drug%20distribution%20into%20tuberculosis%20lesions&journal=Nat%20Med&doi=10.1038%2Fnm.3937&volume=21&issue=10&pages=1223-1227&publication_year=2015&author=Prideaux%2CB&author=Via%2CLE&author=Zimmerman%2CMD&author=Eum%2CS&author=Sarathy%2CJ&author=O%E2%80%99Brien%2CP&author=Chen%2CC&author=Kaya%2CF&author=Weiner%2CDM&author=Chen%2CPY&author=Song%2CT&author=Lee%2CM&author=Shim%2CTS&author=Cho%2CJS&author=Kim%2CW&author=Cho%2CSN&author=Olivier%2CKN&author=Barry%2CCE&author=Dartois%2CV
- How much profit does https://doi.org/10.1016%2FS0140-6736%2818%2931644-1 make?
- How much does http://scholar.google.com/scholar_lookup?&title=Collaborative%20group%20for%20the%20meta-analysis%20of%20individual%20patient%20data%20in%20MDR-TB%20treatment-2017.%20Treatment%20correlates%20of%20successful%20outcomes%20in%20pulmonary%20multidrug-resistant%20tuberculosis%3A%20an%20individual%20patient%20data%20meta-analysis&journal=Lancet.&doi=10.1016%2FS0140-6736%2818%2931644-1&volume=392&issue=10150&pages=821-834&publication_year=2018&author=Ahmad%2CN&author=Ahuja%2CSD&author=Akkerman%2COW generate monthly?
- Explore the financials of https://doi.org/10.1164%2Frccm.201001-0077OC
- Learn how profitable http://scholar.google.com/scholar_lookup?&title=Short%2C%20highly%20effective%2C%20and%20inexpensive%20standardized%20treatment%20of%20multidrug-resistant%20tuberculosis&journal=Am%20J%20Respir%20Crit%20Care%20Med&doi=10.1164%2Frccm.201001-0077OC&volume=182&issue=5&pages=684-692&publication_year=2010&author=Deun%2CA&author=Maug%2CAK&author=Salim%2CMA&author=Das%2CPK&author=Sarker%2CMR&author=Daru%2CP&author=Rieder%2CHL is on a monthly basis
- What are the total earnings of https://doi.org/10.5588%2Fijtld.14.0535?
- What's the monthly income of http://scholar.google.com/scholar_lookup?&title=High%20effectiveness%20of%20a%2012-month%20regimen%20for%20MDR-TB%20patients%20in%20Cameroon&journal=Int%20J%20Tuberc%20Lung%20Dis.&doi=10.5588%2Fijtld.14.0535&volume=19&issue=5&pages=517-524&publication_year=2015&author=Kuaban%2CC&author=Noeske%2CJ&author=Rieder%2CHL&author=Ait-Khaled%2CN&author=Abena%20Foe%2CJL&author=Trebucq%2CA?
- How much does https://doi.org/10.5588%2Fijtld.13.0075 earn?
- How much does http://scholar.google.com/scholar_lookup?&title=High%20cure%20rate%20with%20standardised%20short-course%20multidrug-resistant%20tuberculosis%20treatment%20in%20Niger%3A%20no%20relapses&journal=Int%20J%20Tuberc%20Lung%20Dis.&doi=10.5588%2Fijtld.13.0075&volume=18&issue=10&pages=1188-1194&publication_year=2014&author=Piubello%2CA&author=Harouna%2CSH&author=Souleymane%2CMB&author=Boukary%2CI&author=Morou%2CS&author=Daouda%2CM&author=Hanki%2CY&author=Deun%2CA pull in?
- What is the monthly revenue of https://doi.org/10.1183%2F16000617.0080-2015?
- How much does http://scholar.google.com/scholar_lookup?&title=Short-course%20treatment%20for%20multidrug-resistant%20tuberculosis%3A%20the%20STREAM%20trials&journal=Eur%20Respir%20Rev.&doi=10.1183%2F16000617.0080-2015&volume=25&issue=139&pages=29-35&publication_year=2016&author=Moodley%2CR&author=Godec%2CTR pull in monthly?
- Get to know what's the income of https://doi.org/10.1016%2FS1474-4422%2813%2970168-6
- How much does http://scholar.google.com/scholar_lookup?&title=Tuberculosis%20meningitis%3A%20more%20questions%2C%20still%20too%20few%20answers&journal=Lancet%20Neurol.&doi=10.1016%2FS1474-4422%2813%2970168-6&volume=12&issue=10&pages=999-1010&publication_year=2013&author=Thwaites%2CGE&author=Toorn%2CR&author=Schoeman%2CJ net monthly?
- How much profit does https://doi.org/10.1016%2Fj.ijantimicag.2014.12.027 make?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetic%2Fpharmacodynamic%20analysis%20of%20an%20intensified%20regimen%20containing%20rifampicin%20and%20moxifloxacin%20for%20tuberculosis%20meningitis&journal=Int%20J%20Antimicrob%20Agents&doi=10.1016%2Fj.ijantimicag.2014.12.027&volume=45&issue=5&pages=496-503&publication_year=2015&author=Brake%2CL&author=Dian%2CS&author=Ganiem%2CAR&author=Ruesen%2CC&author=Burger%2CD&author=Donders%2CR&author=Ruslami%2CR&author=Crevel%2CR&author=Aarnoutse%2CR
- What's the monthly income of https://doi.org/10.1016%2FS1473-3099%2813%2970156-7?
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis%E2%80%94authors%E2%80%99%20reply&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2813%2970156-7&volume=13&issue=7&publication_year=2013&author=Ruslami%2CR&author=Ganiem%2CAR&author=Aarnoutse%2CRE&author=Crevel%2CR?
- What's the financial gain of https://doi.org/10.1016%2FS1473-3099%2813%2970101-4?
- How much does http://scholar.google.com/scholar_lookup?&title=Rifampicin%20and%20moxifloxacin%20for%20tuberculous%20meningitis&journal=Lancet%20Infect%20Dis.&doi=10.1016%2FS1473-3099%2813%2970101-4&volume=13&issue=7&pages=568-569&publication_year=2013&author=Akkerman%2CO&author=Pranger%2CA&author=Altena%2CR&author=Werf%2CT&author=Alffenaar%2CJW pull in monthly?
- How much money does https://doi.org/10.1093/cid/cix230 generate?
- Monthly income for https://doi.org/10.1086%2F605576
- What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20of%20moxifloxacin%20in%20cerebrospinal%20fluid%20and%20plasma%20in%20patients%20with%20tuberculous%20meningitis&journal=Clin%20Infect%20Dis&doi=10.1086%2F605576&volume=49&issue=7&pages=1080-1082&publication_year=2009&author=Alffenaar%2CJW&author=Altena%2CR&author=Bokkerink%2CHJ&author=Luijckx%2CGJ&author=Soolingen%2CD&author=Aarnoutse%2CRE&author=Werf%2CTS?
- Profit of https://doi.org/10.1183%2F13993003.00387-2017
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Effectiveness%20and%20safety%20of%20bedaquiline-containing%20regimens%20in%20the%20treatment%20of%20MDR-%20and%20XDR-TB%3A%20a%20multicentre%20study&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.00387-2017&volume=49&issue=5&publication_year=2017&author=Borisov%2CSE&author=Dheda%2CK&author=Enwerem%2CM?
- How much does https://doi.org/10.1183%2F13993003.00040-2016 generate monthly?
- Profit of http://scholar.google.com/scholar_lookup?&title=Incorporating%20therapeutic%20drug%20monitoring%20into%20the%20World%20Health%20Organization%20hierarchy%20of%20tuberculosis%20diagnostics&journal=Eur%20Respir%20J&doi=10.1183%2F13993003.00040-2016&volume=47&issue=6&pages=1867-1869&publication_year=2016&author=Ghimire%2CS&author=Bolhuis%2CMS&author=Sturkenboom%2CMG&author=Akkerman%2COW&author=Lange%2CWC&author=Werf%2CTS&author=Alffenaar%2CJW
- Learn about the earnings of https://doi.org/10.1183%2F13993003.00173-2017
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Therapeutic%20drug%20monitoring%20to%20prevent%20acquired%20drug%20resistance%20of%20fluoroquinolones%20in%20the%20treatment%20of%20tuberculosis&journal=Eur%20Respir%20J.&doi=10.1183%2F13993003.00173-2017&volume=49&issue=4&publication_year=2017&author=Forsman%2CLD&author=Bruchfeld%2CJ&author=Alffenaar%2CJC?
- See how much https://citation-needed.springer.com/v2/references/10.1007/s40265-018-1043-y?format=refman&flavour=references makes per month
- Check the income stats for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=A.%20D.%20Pranger
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22A.%20D.%20Pranger%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en income
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=T.%20S.%20van%20der%20Werf pull in?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22T.%20S.%20van%20der%20Werf%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en net monthly?
- What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20G.%20W.%20Kosterink?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20G.%20W.%20Kosterink%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- How much revenue does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=J.%20W.%20C.%20Alffenaar bring in?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22J.%20W.%20C.%20Alffenaar%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en gross monthly?
- Learn about the earnings of https://s100.copyright.com/AppDispatchServlet?title=The%20Role%20of%20Fluoroquinolones%20in%20the%20Treatment%20of%20Tuberculosis%20in%202019&author=A.%20D.%20Pranger%20et%20al&contentID=10.1007%2Fs40265-018-1043-y©right=The%20Author%28s%29&publication=0012-6667&publicationDate=2019-01-07&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY-NC
- Financial intake of https://crossmark.crossref.org/dialog/?doi=10.1007/s40265-018-1043-y
- How much does https://citation-needed.springer.com/v2/references/10.1007/s40265-018-1043-y?format=refman&flavour=citation rake in every month?
- What's the financial gain of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
- How much does https://www.springernature.com/gp/products make?
- What's the total monthly financial gain of https://www.springernature.com/gp/librarians?
- How much profit is https://www.springernature.com/gp/societies making per month?
- How much does https://www.springernature.com/gp/partners bring in each month?
- What's https://www.springer.com/'s gross income?
- What is the earnings of https://www.nature.com/?
- How much revenue does https://www.biomedcentral.com/ produce monthly?
- Get to know what's the income of https://www.palgrave.com/
- How much cash flow does https://www.apress.com/ have monthly?
- What's the monthly income of https://www.springernature.com/gp/legal/ccpa?
- What's the monthly income of https://www.springernature.com/gp/info/accessibility?
- How much profit does https://support.springernature.com/en/support/home make?
- Income figures for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
- How much profit does https://www.springernature.com/ make?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref